
    
      Estimate the sensibility at the growth hormone in vivo at the children presenting a
      Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth
      hormone (GHD) by the measure of the circulating rates of IGF-I under treatment.
    
  